Esomeprazole: A review of its use in the management of acid-related disorders

Drugs

Volumn 62, Issue 10, 2002, Pages 1503-1538

  Scott, Lesley J ^a   Dunn, Christopher J ^a   Mallarkey, Gordon ^a   Sharpe, Miriam ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acid related dyspepsia; Duodenal ulcer; Esomeprazole; Gastric ulcer; Gastro oesophageal reflux disease; Helicobacter pylori; Peptic ulcer disease; Pharmacodynamics; Pharmacokinetics; Proton pump inhibitor; Therapeutic use

Indexed keywords

AMOXICILLIN; CISAPRIDE; CLARITHROMYCIN; DIAZEPAM; DIGOXIN; ESOMEPRAZOLE; IRON SALT; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; QUINIDINE; RABEPRAZOLE; WARFARIN;

CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DUODENUM ULCER; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HELICOBACTER PYLORI; HUMAN; PHARMACODYNAMICS; REFLUX ESOPHAGITIS; REVIEW; STOMACH ACID SECRETION; TREATMENT OUTCOME; ULCER HEALING;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 0036076988     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262100-00006     Document Type: Review

References (119)

1. Esomeprazole, a new proton pump inhibitor: Pharmacological characteristics and clinical efficacy
2. Omeprazole: A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs
3. Pantoprazole: A review of its pharmacological properties and clinical efficacy in the management of acid-related disorders
4. Rabeprazole: A review of its use in acid-related gastrointestinal disorders
5. Rabeprazole: An update of its use in acid-related disorders
6. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders
7. Lansoprazole: An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders
8. Lansoprazole: An update of its place in the management of acid related disorders
9. Esomeprazole
10. Eradication of Helicobacter pylori infection in the management of patients with dyspepsia and non-ulcer dyspepsia
11. Esomeprazole: A novel proton pump inhibitor for the treatment of acid-related disorders
12. Esomeprazole, the S-isomer of omeprazole, is optically stable in humans
13. Importance of pH control in the management of GERD
14. Sensitivity of oesophageal mucosa to pH in gastro-oesophageal reflux disease
15. Appropriate acid suppression for the management of gastro-oesophageal reflux disease
16. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease
17. Effect of esomeprazole 40mg vs omperazole 40mg on 24-hour intragastric pH in patients with symptoms of gastro-esophageal reflux disease
18. Esomeprazole 20 mg provides more effective acid control than lansoprazole 15 mg
19. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg during single and repeated administration
20. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg
21. Rabeprazole 10mg is equivalent to esomeprazole 20mg in control of gastric pH in healthy volunteers
22. Rabeprazole 20mg is more potent than esomeprazole 20mg in control of gastric pH in healthy volunteers
23. Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg
24. Esomeprazole 40mg provides faster and more effective control than rabeprazole 20mg in patients with symptoms of GERD
25. Lansoprazole 15mg provides as effective acid control as esomeprazole 20mg
26. Speed of onset of intragastric acid control: Lansoprazole and esomeprazole compared
27. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole
28. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects
29. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (POA) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O)
30. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes
31. Esomeprazole 40mg capsules are bioequivalent when administered intact or as the contents mixed with apple sauce
32. Pharmacokinetics of esomeprazole in patients with hepatic impairment
33. Pharmacokinetic study of esomeprazole in the elderly
34. 14C]omeprazole in patients with impaired renal function
35. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole
36. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: Results of three US multicenter, double-blind trials
37. One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease
38. One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease
39. Esomeprazole (40mg) compared with lansoprazole (30mg) in the treatment of erosive esophagitis
40. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial
41. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial
42. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: A randomized, double-blind, placebo-controlled study of efficacy and safety
43. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety
44. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months
45. Esomeprazole 40mg and 20mg is efficacious in the long-term management of patients with endoscopy-negative GORD: A placebo-controlled trial of 'on-demand' therapy for 6 months
46. Comparison of the new PPI esomeprazole, the S-isomer of omeprazole, vs placebo for the treatment of symptomatic GERD
47. Esomeprazole 20mg compared with lansoprazole 15mg for maintenance therapy in patients with healed reflux oesophagitis
48. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis
49. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of Los Angeles classification
50. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis
51. Evidence-based analysis of the benefit of esomeprazole in the treatment of erosive oesophagitis (EE)
52. Does baseline severity of EE impact healing with esomeprazole?
53. Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis
54. Absence of symptoms in erosive esophagitis patients treated with esomeprazole is a highly reliable indicator of healing
55. Noctumal heartbum is rare in patients with erosive esophagitis treated with esomeprazole
56. The impact of baseline severity of erosive esophagitis on heartbum resolution in patients treated with esomeprazole or omeprazole
57. Equivalent efficacy of pantoprazole 40mg and esomeprazole 40mg in patients with GERD
58. Similar reduction of symptom load within 4 weeks of treatment with pantoprazole 40mg or esomeprazole 40mg in patients with moderate to severe GERD
59. Esomeprazole and lansoprazole in the management of patients with reflux oesophagitis (RO): Combining results from two clinical studies
60. Helicobacter pylori: Review of clinical and public health aspects for the practitioner
61. Current European concepts in the management of Helicobacter pylori infection: The Maastricht Consensus Report
62. Guidelines for the management of Helicobacter pylori infection
63. Clinical economics review: Gastrointestinal disease in primary care
64. Quality of life in patients with upper gastrointestinal symptoms from the Domestic/International Gastroenterology Surveillance Study (DIGEST)
65. Cost effectiveness of esomeprazole compared with omeprazole in the acute treatment of patients with reflux oesophagitis in the UK
66. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: Comparison of on-demand esomeprazole with conventional omeprazole treatment strategies
67. In Finland, Sweden and the UK, esomeprazole is cost-effective compared with omeprazole for the acute treatment of patients with reflux oesophagitis
68. Esomeprazdie is cost-effective compared with omeprazole for the acute treatment of patients with non-endoscoped GORD in the UK
69. In Finland, Sweden and the UK, on demand treatment with esomeprazole is cost-effective in patients with GORD without oesophagitis
70. On-demand esomeprazole offers value for money compared with "real-life" maintenance omeprazole therapy for patients with gastro-oesophageal reflux disease (GORD) without oesophagitis
71. Studies in healthy volunteers do not show any electrocardiographic effects with esomeprazole
72. Increasing concerns about chronic proton pump inhibitor use
73. Omeprazole
74. Safety of long-term treatment with a new PPI, esomeprazole in GERD patients
75. Nonerosive reflux disease: Current concepts and dilemmas
76. Guidelines for the diagnostic and therapeutic management of patients with gastro-oesophageal reflux disease: A position statement of the Italian Association of Hospital Gastroenterologists (AIGO), Italian Society of Gastrointestinal Endoscopy (SIED), and Italian Society of Gastroenterology (SIGE)
77. Shortcomings of the first-generation proton pump inhibitors
78. New-generation proton pump inhibitors: Overcoming the limitations of early-generation agents
79. The impact of gastroesophageal reflux disease on health-related quality of life
80. Quality of life and cost of therapy in reflux disease
81. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
82. Strategies for medical management of reflux disease
83. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases
84. Treatment of gastro-oesophageal reflux disease in adults
85. Proton pump inhibitors in acid-related diseases
86. Proton pump inhibitors: Pharmacology and rationale for use in gastrointestinal disorders
87. The proton pump inhibitors: Similarities and differences
88. On-demand therapy for gastro-oesophageal reflux disease
89. Management of severe gastroesophageal reflux disease
90. Recognising atypical manifestations of GERD: Asthma, chest pain, and otolaryngologic disorders may be due to reflux
91. 2-receptor antagonists in the treatment of gastro-oesophageal reflux disease
92. The epidemiology of gastroesophageal reflux disease: What we know and what we need to know
93. What do we know about gastroesophageal reflux disease?
94. Long-term management of gastroesophageal reflux disease and its complications
95. Gastroesophageal reflux disease
96. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response
97. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole
98. Endoscopy-negative acid reflux disease
99. Treating the symptoms of gastro-oesophageal reflux disease: A double-blind comparison of omeprazole and cisapride
100. Reflux disease: The disorder of the third millennium
101. Management of gastro-oesophageal reflux disease in general practice
102. Formulary management of proton pump inhibitors
103. Functional status and well-being of patients with chronic conditions: Results from the Medical Outcomes Study
104. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in health maintenance organization
105. Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life
106. An evidence-based appraisal of reflux disease management: The Genval Workshop Report
107. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?
108. Peptic ulcer disease and current approaches to Helicobacter pylori
109. Gastroduodenal ulcers: Causes, diagnosis, prevention and treatment
110. Debating the role of Helicobacter pylori infection
111. Who should be treated for Helicobacter pylori infection? A review of consensus conferences and guidelines
112. Treatment of Helicobacter pylori infection: Gastrointestinal infections
113. Helicobacter pylori eradication in functional dyspepsia: New evidence for symptomatic benefit
114. Key points from the revised Maastricht Consensus Report: The impact on general practice
115. Treatment of Helicobacter pylori
116. Pharmacological therapy of Helicobacter pylori infection
117. Esomeprazole (nexium)